Enhancing anti-neoplastic activity of metformin in prostate cancer
增强二甲双胍在前列腺癌中的抗肿瘤活性
基本信息
- 批准号:9220731
- 负责人:
- 金额:$ 35.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-02-08 至 2021-01-31
- 项目状态:已结题
- 来源:
- 关键词:5&apos-AMP-activated protein kinaseAccelerationAndrogen ReceptorAndrogensAntidiabetic DrugsAntineoplastic AgentsBiochemicalCancer PatientCastrationCell ProliferationClinicalClinical DataClinical ResearchConsumptionDataDevelopmentDiseaseDisease ProgressionEventFDA approvedFRAP1 geneFosteringGeneticGluconeogenesisGlucoseGoalsGrowth and Development functionHealthHyperinsulinismInvestigationLiverMalignant NeoplasmsMalignant neoplasm of prostateMediatingMetastatic Prostate CancerMetforminMethodologyMissionMitoticMolecularMusNon-Insulin-Dependent Diabetes MellitusOutcomePLK1 genePTEN genePathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPharmacologyPhenotypePhosphorylationPhosphotransferasesProstateProtein BiosynthesisPublic HealthReceptor SignalingResearchResistanceResistance developmentRoleSideSignal PathwaySignal TransductionSystemTSC1 geneTestingTherapeuticTuberous sclerosis protein complexWorkXenograft procedureabirateroneanticancer researchbasecancer therapycancer typecastration resistant prostate cancercell growthchemotherapydesigndiagnostic biomarkerdocetaxeleffective therapyimprovedin vivoinhibitor/antagonistinnovationmTOR InhibitormTOR inhibitionmortalitymouse modelnew therapeutic targetnovelnovel strategiesoverexpressionpredictive markerprostate cancer cellprotein degradationpublic health relevancetherapeutic targettherapy developmenttreatment effecttumor growthtumor progressiontumor xenograft
项目摘要
DESCRIPTION (provided by applicant): Because prostate cancer (PCa) requires androgen for development, castration is the primary treatment for patients with late stage PCa. Because androgen receptor (AR) signaling continues to be active in castration-resistant prostate cancer (CRPC), androgen signaling inhibitors (ASI) are becoming the first line treatment for CRPC. However, two FDA-approved ASIs, abiraterone and enzalutamide, only improve overall patient survival for several months. Thus, it is urgent to identify new targets and develop new approaches to treat ASI-resistant CRPC. Metformin, an antidiabetic drug widely used for over 40 years, is now believed to have anti-neoplastic activity in different types of cancers. Recent clinical data suggests that metformin use may reduce development of CRPC and PCa mortality. However, the detailed molecular mechanisms underlying this very important observation is not completely understood. The long-term goals of this study are to identify druggable signaling pathways that offer more effective treatment options for patients with ASI-resistant CRPC. The objective is to define the role of polo-like kinase 1 (Plk1) in regulating the mTOR (mammalian target of rapamycin) pathway and AR signaling, and to exploit this unique pathway as a novel therapeutic target for ASI- resistant CRPC patients. The central hypothesis is that a combination of Plk1 inhibition with metformin is a new approach to treat ASI-resistant CRPC. This hypothesis will be tested by pursuing two Specific Aims - (1) to dissect how Plk1 phosphorylation of TSC1 (tuberous sclerosis complex 1), a negative regulator of the mTOR pathway, leads to activation of the mTOR pathway in vivo; (2) to determine whether a combination of Plk1 inhibition with metformin is a novel approach to treat ASI-resistant CRPC. These two complementary aims will be accomplished using biochemical analyses of signaling intermediates and employing genetic strategies with inducible PCa mouse models, culture systems and PCa xenograft methodologies. The rationale for the research is that it will be the first to probe the importance f Plk1 to the mTOR/AR pathways and to examine whether a combination of Plk1 inhibition with metformin is a novel approach to treat ASI-resistant CRPC. This contribution is significant because it will (i) define the molecular mechanism by which Plk1 regulates the mTOR/AR signaling; (ii) genetically evaluate how Plk1 cooperates with loss of PTEN signaling; and (iii) validate Plk1 as a critical therapeutic target to enhance the efficacy of metformin. The research is innovative as it approaches the disease from a novel Plk1 signaling pathway, challenging the traditional view that Plk1 functions solely to regulate mitotic events. These studies are poised to
provide a new paradigm for improved patient therapies by identifying the key regulator of the mTOR/AR signaling that is critical for generating and maintaining the CRPC phenotype.
描述(申请人提供):由于前列腺癌(PCa)的发展需要雄激素,因此去势是晚期 PCa 患者的主要治疗方法。由于雄激素受体 (AR) 信号在去势抵抗性前列腺癌 (CRPC) 中持续活跃,因此雄激素信号抑制剂 (ASI) 正在成为 CRPC 的一线治疗方法。然而,FDA 批准的两种 ASI,阿比特龙和恩杂鲁胺,只能提高患者几个月的总体生存率。因此,迫切需要确定新的靶点并开发新的方法来治疗 ASI 耐药的 CRPC。二甲双胍是一种广泛使用 40 多年的抗糖尿病药物,现在被认为对不同类型的癌症具有抗肿瘤活性。最近的临床数据表明,二甲双胍的使用可能会降低 CRPC 的发展和 PCa 死亡率。然而,这一非常重要的观察结果背后的详细分子机制尚未完全了解。这项研究的长期目标是确定可药物化的信号通路,为 ASI 耐药的 CRPC 患者提供更有效的治疗选择。目的是明确 Polo 样激酶 1 (Plk1) 在调节 mTOR(哺乳动物雷帕霉素靶点)通路和 AR 信号传导中的作用,并利用这一独特通路作为 ASI 耐药 CRPC 患者的新治疗靶点。核心假设是 Plk1 抑制与二甲双胍联合治疗是治疗 ASI 耐药性 CRPC 的新方法。这一假设将通过两个具体目标进行检验 - (1) 剖析 TSC1(结节性硬化症复合物 1)(mTOR 通路的负调节因子)的 Plk1 磷酸化如何导致体内 mTOR 通路的激活; (2) 确定 Plk1 抑制与二甲双胍联合治疗是否是治疗 ASI 耐药 CRPC 的新方法。这两个互补的目标将通过信号中间体的生化分析以及采用可诱导 PCa 小鼠模型、培养系统和 PCa 异种移植方法的遗传策略来实现。该研究的基本原理是,它将首次探讨 f Plk1 对 mTOR/AR 通路的重要性,并检查 Plk1 抑制与二甲双胍的组合是否是治疗 ASI 抵抗性 CRPC 的新方法。这一贡献意义重大,因为它将 (i) 定义 Plk1 调节 mTOR/AR 信号传导的分子机制; (ii) 从基因角度评估 Plk1 如何与 PTEN 信号丢失协同作用; (iii) 验证 Plk1 作为增强二甲双胍疗效的关键治疗靶点。这项研究具有创新性,因为它从一种新颖的 Plk1 信号通路研究疾病,挑战了 Plk1 仅发挥调节有丝分裂事件作用的传统观点。这些研究旨在
通过鉴定对于产生和维持 CRPC 表型至关重要的 mTOR/AR 信号传导的关键调节因子,为改善患者治疗提供了新的范例。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOQI LIU其他文献
XIAOQI LIU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOQI LIU', 18)}}的其他基金
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer
靶向 Plk1/Pdcd4/mTORC2 信号传导治疗去势抵抗性前列腺癌
- 批准号:
10731943 - 财政年份:2023
- 资助金额:
$ 35.76万 - 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
- 批准号:
10664904 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
- 批准号:
10437929 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
增强雄激素信号抑制剂在前列腺癌中的功效
- 批准号:
10659141 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Plk1 as a prognostic biomarker for prostate cancer
Plk1 作为前列腺癌的预后生物标志物
- 批准号:
10306968 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
增强雄激素信号抑制剂在前列腺癌中的功效
- 批准号:
10294787 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
增强雄激素信号抑制剂在前列腺癌中的功效
- 批准号:
10427416 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Improving chemotherapy of castration-resistant prostate cancer
改善去势抵抗性前列腺癌的化疗
- 批准号:
9973149 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Improving chemotherapy of castration-resistant prostate cancer.
改善去势抵抗性前列腺癌的化疗。
- 批准号:
10663219 - 财政年份:2016
- 资助金额:
$ 35.76万 - 项目类别:
Improving chemotherapy of castration-resistant prostate cancer.
改善去势抵抗性前列腺癌的化疗。
- 批准号:
10316730 - 财政年份:2016
- 资助金额:
$ 35.76万 - 项目类别:
相似海外基金
Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
- 批准号:
2867610 - 财政年份:2023
- 资助金额:
$ 35.76万 - 项目类别:
Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
- 批准号:
BB/W009633/1 - 财政年份:2022
- 资助金额:
$ 35.76万 - 项目类别:
Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
- 批准号:
459043 - 财政年份:2021
- 资助金额:
$ 35.76万 - 项目类别:
Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2020
- 资助金额:
$ 35.76万 - 项目类别:
Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10561642 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
- 批准号:
532989-2019 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
- 批准号:
2243045 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
- 批准号:
10359032 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
- 批准号:
428988 - 财政年份:2019
- 资助金额:
$ 35.76万 - 项目类别:
Studentship Programs